Physician profile
Jerome B Blumenthal
NPI 1518957844
$393.74
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $177.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $159.14 | 2019-2020 | |
| Abbvie INC. | $54.60 | 2019-2020 | |
| Novo Nordisk INC | $44.50 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $18.18 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.55 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $17.32 | 2020 | |
| Lilly USA, LLC | $16.69 | 2019 | |
| Radius Health, INC. | $15.51 | 2020 | |
| Amgen INC. | $13.72 | 2019 | |
| Merck Sharp & Dohme LLC | $13.45 | 2020 | |
| Antares Pharma, INC. | $11.57 | 2020 | |
| Becton, Dickinson and Company | $11.51 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome Blumenthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.